AKT1 and melanoma: The finding that the exposure of BRAF-mutant melanoma cells to our G4 ligand resulted in modulation of the expression levels of genes belonging to signaling pathways that are relevant to melanoma cell survival and drug-resistance prompted us to investigate whether the compound interacted with specific G4 targets at the interplay of RAS/RAF/MAPK and PI3K/AKT, as well as the intrinsic apoptosis pathways.